Tag Archives: TAVR

SENTINEL: Protección cerebral en TAVI

Cerebral Protection Devices during TAVR in the Daily Practice

The theory behind the use of cerebral protection devices during TAVR is good, but hard to test. The daily practice provides a far bigger number of patients, and therefore might be able to better show how to prevent one of the hardest events during TAVR.  This study resorted to Germany’s TAVR database between 2015 and

TAVI SURAVI

TAVR vs. the Least Invasive Surgically Implanted Valve

Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional bioprostheses, which require several stitches. These valves, which shorten surgical times, could compete with transcatheter-implanted valves (transcatheter aortic valve replacement, TAVR). The German Aortic Valve Registry analyzed 16,473 patients who underwent surgical aortic valve replacement with either a current-generation

pacientes anticoagulados por fibrilación auricular que reciben angioplastia tratamiento

The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists. The purpose of this paper published in JACC Interv was to compare long-term results between classic vitamin K antagonists and novel direct anticoagulant agents in patients with

Es un hecho: la protección cerebral en TAVI logró demostrar que reduce el stroke y la muerte

Silent Stroke During TAVR and Early Cognitive Impairment

Silent stroke is common after transcatheter aortic valve replacement (TAVR). Co-morbidities such as diabetes or chronic renal failure, as well as procedural factors such as pre-dilation, increase the risk of silent stroke. While many events of silent stroke have an early effect on cognition, it is necessary to learn whether the impairment is sustained over

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable Acurate neo and the balloon expandable Sapien 3.  The SCOPE 1 (Safety and Efficacy of the Symetis ACURATE neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis) compared the balloon expandable Sapien 3 (which has probably more data) against

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. However, surgeons argue that these cases fail to consider patients from daily clinical practice, but rather include a population that has been carefully selected for randomized trials. Patients with non-tricuspid aortic stenosis, with severe

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Cusp Overlap for Higher CoreValve Implantation

Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker implantation. Valve implantation 3 to 5 mm below the aortic annulus in a projection coaxial to the device is recommended. The problem is this is rarely in the annular plane of the valve. Ideal annular plane projection is

El aumento de la experiencia de los operadores mejora los resultados en el TAVI

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery, but the initial difference in death and stroke in favor of TAVR started to shrink.  In addition, there was higher risk of valve thrombosis in TAVR patients.  The PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are treating a much wider array of patients ranging from low risk to inoperable.  And there is yet one more important point: hypo-attenuated leaflet thickening diagnosed by CT. We are still unaware of the impact they have on device

Top